The combination of axi-cel and rituximab showed high efficacy in refractory LBCL, with a 73% complete response rate and 88% overall response rate. Safety was favorable, with no new signals; 96% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback